# Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

> **NCT02404389** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 82 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Investigational Treatment
- **DRUG:** Active comparator

## Key facts

- **NCT ID:** NCT02404389
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-05
- **Primary completion:** 2016-01-27
- **Final completion:** 2016-01-27
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404389, "Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02404389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*